Pharming Announces Financing Plans for Closing of RUCONEST® North American Rights Acquisition
Financial updatesPharming Group N.V. announces its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016.